These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23292237)

  • 1. Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation.
    Ito Y; Miyamoto T; Chong Y; Aoki T; Kato K; Akashi K; Kamimura T
    Bone Marrow Transplant; 2013 Jul; 48(7):998-9. PubMed ID: 23292237
    [No Abstract]   [Full Text] [Related]  

  • 2. Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma.
    Haji S; Kiyasu J; Choi I; Suehiro Y; Toyoda K; Tsuda M; Takamatsu A; Nakashima Y; Miyoshi H; Shiratsuchi M; Yamasaki S; Uike N; Abe Y
    Bone Marrow Transplant; 2016 Mar; 51(3):432-4. PubMed ID: 26524267
    [No Abstract]   [Full Text] [Related]  

  • 3. [Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy].
    Suwabe T; Shibasaki Y; Kaihatsu A; Katagiri T; Miyakoshi S; Fuse K; Kobayashi H; Ushiki T; Moriyama M; Takizawa J; Narita M; Sone H; Masuko M
    Rinsho Ketsueki; 2017; 58(1):32-36. PubMed ID: 28190863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of a patient with adult T cell leukemia/lymphoma using anti-CC chemokine receptor 4 monoclonal antibody mogamulizumab followed by allogeneic hematopoietic stem cell transplantation.
    Motohashi K; Suzuki T; Kishimoto K; Numata A; Nakajima Y; Tachibana T; Ohshima R; Kuwabara H; Tanaka M; Tomita N; Ishigatsubo Y; Fujisawa S
    Int J Hematol; 2013 Aug; 98(2):258-60. PubMed ID: 23801427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies.
    Ohyama Y; Kumode T; Eguchi G; Yamaguchi T; Maeda Y
    Ann Hematol; 2014 Jan; 93(1):169-71. PubMed ID: 23612772
    [No Abstract]   [Full Text] [Related]  

  • 9. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 11. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
    Ishida T; Joh T; Uike N; Yamamoto K; Utsunomiya A; Yoshida S; Saburi Y; Miyamoto T; Takemoto S; Suzushima H; Tsukasaki K; Nosaka K; Fujiwara H; Ishitsuka K; Inagaki H; Ogura M; Akinaga S; Tomonaga M; Tobinai K; Ueda R
    J Clin Oncol; 2012 Mar; 30(8):837-42. PubMed ID: 22312108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma: clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation.
    Fuji S; Utsunomiya A; Inoue Y; Miyagi T; Owatari S; Sawayama Y; Moriuchi Y; Choi I; Shindo T; Yoshida SI; Yamasaki S; Yamaguchi T; Fukuda T
    Haematologica; 2018 May; 103(5):e211-e214. PubMed ID: 29371324
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
    Tobinai K; Takahashi T; Akinaga S
    Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
    Zinzani PL; Karlin L; Radford J; Caballero D; Fields P; Chamuleau ME; d'Amore F; Haioun C; Thieblemont C; González-Barca E; García CG; Johnson PW; van Imhoff GW; Ng T; Dwyer K; Morschhauser F
    Haematologica; 2016 Oct; 101(10):e407-e410. PubMed ID: 27418646
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab.
    Furukawa M; Ikeda K; Ohkawara H; Saito S; Takahashi H; Ueda K; Matsumoto H; Hashimoto Y; Ohto H; Ogawa K; Takeishi Y
    Int J Hematol; 2015 Oct; 102(4):498-505. PubMed ID: 25975265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.
    Kato K; Miyamoto T; Numata A; Nakaike T; Oka H; Yurino A; Kuriyama T; Mori Y; Yamasaki S; Muta T; Takenaka K; Iwasaki H; Teshima T; Akashi K
    Int J Hematol; 2013 Mar; 97(3):430-2. PubMed ID: 23397210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of thymus and activation-regulated chemokine and macrophage-derived chemokine by CCR4+ adult T-cell leukemia cells.
    Shimauchi T; Imai S; Hino R; Tokura Y
    Clin Cancer Res; 2005 Mar; 11(6):2427-35. PubMed ID: 15788694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab.
    Ishitsuka K; Murahashi M; Katsuya H; Mogi A; Masaki M; Kawai C; Goto T; Ishizu M; Ikari Y; Takamatsu Y; Ishibashi H; Nimura S; Takeshita M; Tamura K
    Int J Hematol; 2015 Oct; 102(4):493-7. PubMed ID: 25995001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
    Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
    Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous adverse reaction of mogamulizumab, an anti-CC chemokine receptor 4 monoclonal antibody: Shared histopathological features with thymoma-associated multi-organ autoimmunity.
    Kanno K; Honma M; Ishida-Yamamoto A
    J Dermatol; 2017 Jun; 44(6):e117-e118. PubMed ID: 28026038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.